Total Results: 7178
State Sen. Ed Hernandez’s drug pricing transparency bill faltered, but that hasn’t stopped him from introducing a measure to urge Congress to investigate EpiPen maker Mylan.
The California measure would protect consumers and provide better reimbursement for care, supporters say.
Department of Health and Human Services researchers compared counties across state borders and adjusted for several differences between them. Their calculations led them to conclude that expanding Medicaid helped produce to marketplace premiums that were 7 percent lower.
The Wall Street Journal reports that the burden of health care costs is shifting in greater part to working middle-class families, in large part because of higher deductibles in insurance plans.
A Sonoma Country family feels the pinch of the high price of this emergency allergy medicine. Meanwhile, news outlets explore recent developments such as the response by Mylan, the company that markets the EpiPen, as well as positions being taken by lawmakers, parents, public figures and even Mylan’s CEO.
The drug Lantus is among a new generation of diabetes medications that is difficult for governments — and consumers — to afford.
As the national controversy continues surrounding the high cost of EpiPens — the most recent to focus attention on drug costs, the San Francisco Chronicle reports on this November ballot measure, which would prohibit state agencies from paying more for drugs than does the U.S. Department of Veterans Affairs.
Researchers examine thousands of studies to determine why prices for medications have climbed and what might be done about it.
The bill would help consumers avoid pricey bills from out-of-network docs.
Liz Helms of the California Chronic Care Coalition takes some surprising positions on prescription drug costs.